Stay updated with breaking news from Grouplp Column. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target […]
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) – Analysts at B. Riley reduced their FY2023 EPS estimates for shares of NGM Biopharmaceuticals in a research note issued to investors on Wednesday, March 29th. B. Riley analyst M. Mamtani now expects that the company will earn ($1.79) per share for the year, down from their previous […]
NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) had its target price decreased by B. Riley from $8.00 to $7.00 in a research report sent to investors on Thursday morning, The Fly reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for NGM Biopharmaceuticals’ Q1 2023 earnings at ($0.52) EPS, […]
NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) had its price target decreased by B. Riley from $8.00 to $7.00 in a research note issued to investors on Thursday, The Fly reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for NGM Biopharmaceuticals’ Q1 2023 earnings at ($0.52) EPS, Q2 […]
Deutsche Bank AG increased its holdings in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) by 53.5% in the second quarter, Holdings Channel.com reports. The firm owned 263,912 shares of the company’s stock after purchasing an additional 92,018 shares during the period. Deutsche Bank AG’s holdings in NGM Biopharmaceuticals were worth $3,384,000 at the end of […]